Current state of immunotherapy for glioblastoma

  title={Current state of immunotherapy for glioblastoma},
  author={M. Lim and Y. Xia and C. Bettegowda and M. Weller},
  journal={Nature Reviews Clinical Oncology},
  • M. Lim, Y. Xia, +1 author M. Weller
  • Published 2018
  • Medicine
  • Nature Reviews Clinical Oncology
  • Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma. Conventional therapies, including surgery, radiotherapy, and pharmacotherapy (typically chemotherapy with temozolomide), have not resulted in major improvements in the survival outcomes of patients with glioblastoma. Reasons for this lack of progress include invasive tumour growth in an essential organ, which limits the utility of… CONTINUE READING
    251 Citations
    Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
    • PDF
    The Path Toward PET-Guided Radiation Therapy for Glioblastoma in Laboratory Animals: A Mini Review
    • 7
    • PDF
    Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
    • Highly Influenced
    • PDF
    Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
    • 1
    • PDF
    Recent Advances in Immune Cell Therapy for Glioblastoma
    • Highly Influenced
    • PDF
    Glioblastoma Therapy in the Age of Molecular Medicine.
    • 26


    Immunosuppressive mechanisms in glioblastoma.
    • 149
    • PDF
    Vaccine-based immunotherapeutic approaches to gliomas and beyond
    • 70
    • PDF
    Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    • 540